Mauna Kea Technologies has enrolled more than 200 patients in its CONTACT II clinical study.
Here are three things to know:
1. The study focuses on the characterization of pancreatic cysts with needle-based confocal laser endomicroscopy.
2. Mauna Kea Technologies is the creator of Cellvizio, a multidisciplinary confocal laser endomicroscopy platform.
3. Further clinical evidence of the safety and efficacy of with needle-based confocal laser endomicroscopy is expected to strengthen the CLE technology.